Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) [Phase 3]

View source ↗

Summary

Phase 3 STOP-V2 trial evaluating povorcitinib in nonsegmental vitiligo is currently active and not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonsegmental Vitiligo

Drugs mentioned

• Povorcitinib (povorcitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: NonSegmental Vitiligo | Phase 3 | Status: ACTIVE_NOT_RECRUITING